GLP-1 receptor agonists
Oral versions add another way to take these drugs, but clinical results and access differ. Negative trials, reimbursement rules and each product's economics limit how far use can expand.
Research snapshot · updated Nov 12, 2026
State of the art (2026)
Pills have arrived. The FDA approved an oral form of Wegovy in December 2025 and Lilly's Foundayo (orforglipron) for weight management on 1 April 2026. Lilly has also filed Foundayo for type 2 diabetes. Among newer injections, Lilly's retatrutide has positive Phase 3 results and a US filing planned for early 2027. Novo Nordisk's CagriSema is under FDA review, with a decision expected by the company in late 2026, after it produced less weight loss than tirzepatide in a head-to-head trial. Semaglutide failed in two Alzheimer's trials in November 2025. Our view: these drugs now compete on results in specific groups of patients, side effects, insurance coverage and cost, as well as on headline weight loss.
Novo Nordisk and Lilly compete on manufacturing, evidence and coverage
Novo Nordisk and Eli Lilly make the leading drugs in this class: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). They compete on manufacturing capacity, trial evidence and insurance coverage. The FDA declared the US shortage of semaglutide injection over in February 2025, which ended the shortage-based permission for pharmacies to make copies. Those copies were never approved generics, and the end of a shortage changes nothing about patents. Patent expiry dates and generic rules differ by product and by country. We do not have a dated market-share figure that we trust.
Pills are easier to take, but cost and coverage still limit use
Foundayo can be taken with or without food, according to its FDA label. A pill is easier to store, ship and take than an injection, and some patients will prefer it. That does not mean everyone who avoided injections will now start treatment. Insurance coverage, cost, side effects, medical reasons not to take the drug and how long people stay on it still vary by product. Comparing a pill's results with an injection's needs a trial in the same kind of patients using the same measure.
Newer drugs can widen the market and compete for the same patients
New drugs and new forms can bring in people who would not take an injection, replace an existing treatment, or suit a different group of patients. Which of these happens cannot be read from weight-loss percentages taken from separate trials, because trials differ in who took part, how long they ran and how drop-outs were counted. Side effects and insurers' rules matter as much. There is no agreed path in which patients move from today's drugs to stronger injections and then to a maintenance pill.
Explore the deeper analysis in CanaryIQ
Explore what is covered below. These previews show the structure; log in to read the full analysis.
Signal stack
Evidence stacked leading → lagging
10 signals
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
3 tracked
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what, and who depends on whom
48 players · 6 layers
Landscape map
Who builds what, and who depends on whom
Catalyst calendar
Dated events that will move the position
5 ahead
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
3 milestones
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers, each with a condition for removing it
20 · 20
Watchlists
Companies, people and papers, each with a condition for removing it
Decision frameworks
What our view means for your job
Locked
Decision frameworks
What our view means for your job
Thesis changelog
When our view changed, and why
9 updates
Thesis changelog
When our view changed, and why
Change our mind
6 disconfirming conditions
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and a record of every time our view on GLP-1 receptor agonists has changed. All of it is in CanaryIQ.